MiRDA-C Study: Understanding Colorectal Cancer Recurrence
This study, called MiRDA-C, is looking at whether changes in your blood, specifically circulating tumor DNA (ctDNA) and other cancer-related molecules, can help doctors predict if colorectal cancer might return or spread. You could be eligible if you are at least 18 years old and have colorectal adenocarcinoma that doctors believe can be treated with the goal of a cure. The study aims to see if monitoring these blood changes can improve how doctors detect cancer recurrence after you've finished curative treatments. This information could help us better understand how to predict if colorectal cancer will come back.
- Study design
- This is an observational study planning to enroll 1000 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would provide blood and tissue samples, and your medical records would be reviewed. Blood samples are collected at various times, including during treatment and up to four times a year for up to five years.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for up to five years to monitor for cancer recurrence.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
At a glance
Conditions
NCT04739072
Where you'd take part
This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
M D Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Banner - MD Anderson Cancer Center
Gilbert, Arizonano site contact published
Terminated
Baptist- MD Anderson Cancer Center
Jacksonville, Floridano site contact published
Terminated
Baylor Scott & White Research Institute
Temple, Texasno site contact published
Terminated
Cooper Hospital UNIV MED CTR.
Camden, New Jerseyno site contact published
Terminated
Houston Methodist Cancer Center
Houston, Texasno site contact published
Terminated
St. Luke's Cancer Institute
Boise, Idahono site contact published
Terminated
The Queen's Medical Center
Honolulu, Hawaiino site contact published
Terminated
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Arvind Dasari · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Analysis of deoxyribonucleic (DNA), ribonucleic acid (RNA), and proteomic alterations from plasmaUp to 5 years
To detect circulating tumor DNA (ctDNA) in plasma samples from patients with colorectal cancer (CRC) who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology.
- Detection of recurrences post completion of curative therapiesUp to 5 years
To detect ctDNA in plasma samples from patients with CRC who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology.